Source:http://linkedlifedata.com/resource/pubmed/id/15272598
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
2004-7-26
|
| pubmed:abstractText |
From 1998 to 2001, 5 consecutive cases of AML/TMDS entered our hospital and achieved complete remission (CR) with continuous drip infusion of low-dose etoposide and low-dose Ara-C combined with mitoxantrone (MEtA regimen). The ages of the 5 patients (4 males and 1 female) ranged 32 to 50 years-old, respectively. WBCs were 1,560-45,150/microl, blasts were 12-62%. Bone marrow aspirates revealed trilineage myelodysplasia with various number of blasts. These patients had an acute onset and no preceding hematologic disorders. They were diagnosed M2/TMDS or M4/TMDS. Continuous drip infusion of etoposide (50 mg/body/day) and Ara-C (30 mg/body/day) were given for 11-14 days and a bolus injection of mitoxantrone (8 mg/m2) was added for 2-3 days. Patient 5 was given additional MIT (6.7 mg/m2 on day 6). All cases achieved CR in 21-24 days after the end of the therapy. Toxicities were nausea, vomiting, stomatitis, alopecia and fever due to infection. All were well tolerable, however. Two patients are alive more than 4 years without relapse. MEtA regimen is available for AML/TMDS.
|
| pubmed:language |
jpn
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0385-0684
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
31
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1119-23
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:15272598-Adult,
pubmed-meshheading:15272598-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15272598-Cell Lineage,
pubmed-meshheading:15272598-Cytarabine,
pubmed-meshheading:15272598-Disease-Free Survival,
pubmed-meshheading:15272598-Dose-Response Relationship, Drug,
pubmed-meshheading:15272598-Drug Administration Schedule,
pubmed-meshheading:15272598-Etoposide,
pubmed-meshheading:15272598-Female,
pubmed-meshheading:15272598-Humans,
pubmed-meshheading:15272598-Leukemia, Myeloid, Acute,
pubmed-meshheading:15272598-Leukemia, Myelomonocytic, Acute,
pubmed-meshheading:15272598-Male,
pubmed-meshheading:15272598-Middle Aged,
pubmed-meshheading:15272598-Mitoxantrone,
pubmed-meshheading:15272598-Myelodysplastic Syndromes,
pubmed-meshheading:15272598-Remission Induction
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
[Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
|
| pubmed:affiliation |
Dept. of Hematology, Sakai Municipal Hospital.
|
| pubmed:publicationType |
Journal Article,
English Abstract,
Case Reports
|